home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Targeting Psychosis

  March, 6 2008 9:08
your information resource in human molecular genetics
A pair of receptors in the brain that react to hallucinogenic drugs are identified as a potential target for the treatment of psychosis, in a paper published online in Nature this week. The serotonin and glutamate receptors form a complex in the brain that triggers responses to drugs such as LSD and psilocybin.

Some antipsychotic drugs target the serotonin 5-HT2A receptors (2AR), and some hallucinogenic drugs act on the same receptors. Stuart Sealfon and colleagues show that the metabotropic glutamate receptor mGluR2, a drug target for schizophrenia, interacts with 2AR to form a functional complex in the brain that is activated by hallucinogenic drugs. Activating mGluR2 blocks the effects of the hallucinogenic drugs in mice, and the normal balance of these receptors is disrupted in the brains of schizophrenic patients. The researchers believe that the complex may be a promising new target for treating psychosis.

Author contact:

Stuart Sealfon (Mount Sinai School of Medicine, New York, NY, USA)
E-mail: Stuart.Sealfon@mssm.edu

(C) Nature press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.